Cargando…
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells
Background: Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262243/ https://www.ncbi.nlm.nih.gov/pubmed/34257548 http://dx.doi.org/10.3389/pore.2021.597499 |
_version_ | 1783719153960484864 |
---|---|
author | Cruz-Rico, Graciela Avilés-Salas, Alejandro Popa-Navarro, Xitlally Lara-Mejía, Luis Catalán, Rodrigo Sánchez-Reyes, Roberto López-Sánchez, Dennis Cabrera-Miranda, Luis Aquiles Maldonado-Martínez, Héctor Samtani-Bassarmal, Suraj Arrieta, Oscar |
author_facet | Cruz-Rico, Graciela Avilés-Salas, Alejandro Popa-Navarro, Xitlally Lara-Mejía, Luis Catalán, Rodrigo Sánchez-Reyes, Roberto López-Sánchez, Dennis Cabrera-Miranda, Luis Aquiles Maldonado-Martínez, Héctor Samtani-Bassarmal, Suraj Arrieta, Oscar |
author_sort | Cruz-Rico, Graciela |
collection | PubMed |
description | Background: Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the frequency of PD-L1 expression according to the IASLC/ATS/ERS classification and other relevant histological and clinical features. Patients and Methods: PD-L1 expression was assessed by immunohistochemistry (IHC). According to its positivity in tumor cells membrane, we stratified patients in three different tumor proportions score (TPS) cut-off points: a) <1% (negative), b) between 1 and 49%, and c) ≥50%; afterward, we analyzed the association among PD-L1 expression and lung adenocarcinoma (LADC) predominant subtypes, as well as other clinical features. As an exploratory outcome we evaluated if a PD-L1 TPS score ≥15% was useful as a biomarker for determining survival. Results: A total of 240 patients were included to our final analysis. Median age at diagnosis was 65 years (range 23–94 years). A PD-L1 TPS ≥1% was observed in 52.5% of the entire cohort; regarding specific predominant histological patterns, a PD-L1 TPS ≥1 was documented in 31.2% of patients with predominant-lepidic pattern, 46.2% of patients with predominant-acinar pattern, 42.8% of patients with a predominant-papillary pattern, and 68.7% of patients with predominant-solid pattern (p = 0.002). On the other hand, proportion of tumors with PD-L1 TPS ≥50% was not significantly different among adenocarcinoma subtypes. At the univariate survival analysis, a PD-L1 TPS cut-off value of ≥15% was associated with a worse PFS and OS. Conclusion: According to IASLC/ATS/ERS lung adenocarcinoma classification, the predominant-solid pattern is associated with a higher proportion of PD-L1 positive samples, no subtype was identified to be associated with a high (≥50%) TPS PD-L1. |
format | Online Article Text |
id | pubmed-8262243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82622432021-07-12 Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells Cruz-Rico, Graciela Avilés-Salas, Alejandro Popa-Navarro, Xitlally Lara-Mejía, Luis Catalán, Rodrigo Sánchez-Reyes, Roberto López-Sánchez, Dennis Cabrera-Miranda, Luis Aquiles Maldonado-Martínez, Héctor Samtani-Bassarmal, Suraj Arrieta, Oscar Pathol Oncol Res Society Journal Archive Background: Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the frequency of PD-L1 expression according to the IASLC/ATS/ERS classification and other relevant histological and clinical features. Patients and Methods: PD-L1 expression was assessed by immunohistochemistry (IHC). According to its positivity in tumor cells membrane, we stratified patients in three different tumor proportions score (TPS) cut-off points: a) <1% (negative), b) between 1 and 49%, and c) ≥50%; afterward, we analyzed the association among PD-L1 expression and lung adenocarcinoma (LADC) predominant subtypes, as well as other clinical features. As an exploratory outcome we evaluated if a PD-L1 TPS score ≥15% was useful as a biomarker for determining survival. Results: A total of 240 patients were included to our final analysis. Median age at diagnosis was 65 years (range 23–94 years). A PD-L1 TPS ≥1% was observed in 52.5% of the entire cohort; regarding specific predominant histological patterns, a PD-L1 TPS ≥1 was documented in 31.2% of patients with predominant-lepidic pattern, 46.2% of patients with predominant-acinar pattern, 42.8% of patients with a predominant-papillary pattern, and 68.7% of patients with predominant-solid pattern (p = 0.002). On the other hand, proportion of tumors with PD-L1 TPS ≥50% was not significantly different among adenocarcinoma subtypes. At the univariate survival analysis, a PD-L1 TPS cut-off value of ≥15% was associated with a worse PFS and OS. Conclusion: According to IASLC/ATS/ERS lung adenocarcinoma classification, the predominant-solid pattern is associated with a higher proportion of PD-L1 positive samples, no subtype was identified to be associated with a high (≥50%) TPS PD-L1. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8262243/ /pubmed/34257548 http://dx.doi.org/10.3389/pore.2021.597499 Text en Copyright © 2021 Cruz-Rico, Avilés-Salas, Popa-Navarro, Lara-Mejía, Catalán, Sánchez-Reyes, López-Sánchez, Cabrera-Miranda, Aquiles Maldonado-Martínez, Samtani-Bassarmal and Arrieta. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Society Journal Archive Cruz-Rico, Graciela Avilés-Salas, Alejandro Popa-Navarro, Xitlally Lara-Mejía, Luis Catalán, Rodrigo Sánchez-Reyes, Roberto López-Sánchez, Dennis Cabrera-Miranda, Luis Aquiles Maldonado-Martínez, Héctor Samtani-Bassarmal, Suraj Arrieta, Oscar Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells |
title | Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells |
title_full | Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells |
title_fullStr | Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells |
title_full_unstemmed | Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells |
title_short | Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells |
title_sort | association of lung adenocarcinoma subtypes according to the iaslc/ats/ers classification and programmed cell death ligand 1 (pd-l1) expression in tumor cells |
topic | Society Journal Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262243/ https://www.ncbi.nlm.nih.gov/pubmed/34257548 http://dx.doi.org/10.3389/pore.2021.597499 |
work_keys_str_mv | AT cruzricograciela associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT avilessalasalejandro associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT popanavarroxitlally associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT laramejialuis associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT catalanrodrigo associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT sanchezreyesroberto associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT lopezsanchezdennis associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT cabreramirandaluis associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT aquilesmaldonadomartinezhector associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT samtanibassarmalsuraj associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells AT arrietaoscar associationoflungadenocarcinomasubtypesaccordingtotheiaslcatsersclassificationandprogrammedcelldeathligand1pdl1expressionintumorcells |